venglustat

News

November date set for FDA decision on Sanofi's Gaucher drug

The FDA has started a priority review of Sanofi's brain-acting Gaucher disease therapy venglustat, with an action date of 25th November.

News

Mixed data mars Sanofi's venglustat programme

Sanofi has reported positive phase 3 results with venglustat in Gaucher disease, but the drug missed the mark in a Fabry disease trial.

News

Sanofi's venglustat bombs again, but isn't dead yet

Shortly after failing a Parkinson's disease study, Sanofi's venglustat has missed the mark in another trial in autosomal dominant polycystic kidney disease (ADPKD), whittling down the list

November date set for FDA decision on Sanofi's Gaucher drug

Mixed data mars Sanofi's venglustat programme

Sanofi's venglustat bombs again, but isn't dead yet

Zymeworks cuts deal to buy Theravance for $929m in cash

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks